These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9291169)

  • 1. Intravenous immunoglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis--the Israeli experience. MS Study Group.
    Achiron A; Rotstein Z; Barak Y; Sarova-Pinhas I
    Mult Scler; 1997 Apr; 3(2):142-4. PubMed ID: 9291169
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
    Humle Jorgensen S; Sorensen PS
    J Neurol Sci; 2005 Jun; 233(1-2):61-5. PubMed ID: 15949496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action.
    Achiron A; Gilad R; Margalit R; Gabbay U; Sarova-Pinhas I; Cohen IR; Melamed E; Lider O; Noy S; Ziv I
    J Neurol Neurosurg Psychiatry; 1994 Nov; 57 Suppl(Suppl):57-61. PubMed ID: 7964856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The trimolecular complex as a target for specific immunotherapy in experimental autoimmune encephalomyelitis--applications for multiple sclerosis and other human autoimmune disease].
    Miller A; Weiner HL; Abramsky O
    Harefuah; 1992 Aug; 123(3-4):110-5. PubMed ID: 1516860
    [No Abstract]   [Full Text] [Related]  

  • 5. T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.
    O'Brien K; Gran B; Rostami A
    Immunotherapy; 2010 Jan; 2(1):99-115. PubMed ID: 20231863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promotion of endogenous remyelination in multiple sclerosis.
    Lucchinetti CF; Noseworthy JH; Rodriguez M
    Mult Scler; 1997 Apr; 3(2):71-5. PubMed ID: 9291156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Animal models for multiple sclerosis.
    Owens T
    Adv Neurol; 2006; 98():77-89. PubMed ID: 16400828
    [No Abstract]   [Full Text] [Related]  

  • 8. A shift in encephalitogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulins (IVIg).
    Pashov A; Bellon B; Kaveri SV; Kazatchkine MD
    Mult Scler; 1997 Apr; 3(2):153-6. PubMed ID: 9291172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion.
    Achiron A; Margalit R; Hershkoviz R; Markovits D; Reshef T; Melamed E; Cohen IR; Lider O
    J Clin Invest; 1994 Feb; 93(2):600-5. PubMed ID: 8113397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment.
    Lapointe BM; Herx LM; Gill V; Metz LM; Kubes P
    Brain; 2004 Dec; 127(Pt 12):2649-56. PubMed ID: 15355874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopathogenic mechanisms in experimental allergic encephalomyelitis.
    Kálmán B; Lublin FD
    Curr Opin Neurol Neurosurg; 1993 Apr; 6(2):182-8. PubMed ID: 7683223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous polyclonal human immunoglobulins in multiple sclerosis.
    Soelberg Sorensen P
    Neurodegener Dis; 2008; 5(1):8-15. PubMed ID: 18075269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell receptor peptides for the vaccination therapy of multiple sclerosis.
    Brocke S
    Ernst Schering Res Found Workshop; 2000; (30):167-79. PubMed ID: 10943323
    [No Abstract]   [Full Text] [Related]  

  • 14. The T lymphocyte in experimental allergic encephalomyelitis.
    Zamvil SS; Steinman L
    Annu Rev Immunol; 1990; 8():579-621. PubMed ID: 2188675
    [No Abstract]   [Full Text] [Related]  

  • 15. [Experimental autoimmune encephalomyelitis].
    Cornet A; Vizler C; Liblau R
    Rev Neurol (Paris); 1998 Sep; 154(8-9):586-91. PubMed ID: 9809373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis.
    Martin R; McFarland HF
    Crit Rev Clin Lab Sci; 1995; 32(2):121-82. PubMed ID: 7598789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis: human model for EAE?
    Hohlfeld R
    Eur J Immunol; 2009 Aug; 39(8):2036-9. PubMed ID: 19672899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EAE: imperfect but useful models of multiple sclerosis.
    't Hart BA; Gran B; Weissert R
    Trends Mol Med; 2011 Mar; 17(3):119-25. PubMed ID: 21251877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors.
    Kassis I; Petrou P; Halimi M; Karussis D
    Immunol Lett; 2013; 154(1-2):70-6. PubMed ID: 23994102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costimulatory molecule expression on leukocytes from mice with experimental autoimmune encephalomyelitis treated with IFN-beta.
    Hallal DE; Farias AS; Oliveira EC; Diaz-Bardales BM; Brandão CO; Protti GG; Pereira FG; Metze IL; Santos LM
    J Interferon Cytokine Res; 2003 Jun; 23(6):293-8. PubMed ID: 12859855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.